Cargando…

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

BACKGROUND: We performed a time-course microarray experiment to define the transcriptional response to carboplatin in vitro, and to correlate this with clinical outcome in epithelial ovarian cancer (EOC). RNA was isolated from carboplatin and control-treated 36M2 ovarian cancer cells at several time...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konstantinopoulos, Panagiotis A, Fountzilas, Elena, Pillay, Kamana, Zerbini, Luiz F, Libermann, Towia A, Cannistra, Stephen A, Spentzos, Dimitrios
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613398/ https://www.ncbi.nlm.nih.gov/pubmed/19038057 http://dx.doi.org/10.1186/1755-8794-1-59

Ejemplares similares

Analysis of Multiple Sarcoma Expression Datasets: Implications for Classification, Oncogenic Pathway Activation and Chemotherapy Resistance
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2010)

Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2011)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
por: Neil, Alexander J., et al.
Publicado: (2023)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
por: Pénzváltó, Zsófia, et al.
Publicado: (2014)

Structural Analysis of Human Respiratory Syncytial Virus P Protein: Identification of Intrinsically Disordered Domains
por: Simabuco, Fernando M., et al.
Publicado: (2011)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma
por: Paccez, Juliano D., et al.
Publicado: (2015)

A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study
por: Fountzilas, Elena, et al.
Publicado: (2012)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Genomic Counter-Stress Changes Induced by the Relaxation Response
por: Dusek, Jeffery A., et al.
Publicado: (2008)

Correction: Genomic Counter-Stress Changes Induced by the Relaxation Response
por: Dusek, Jeffery A., et al.
Publicado: (2017)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2016)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway
por: Vava, Akhona, et al.
Publicado: (2023)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Combinatorial Effect of Non-Steroidal Anti-inflammatory Drugs and NF-κB Inhibitors in Ovarian Cancer Therapy
por: Zerbini, Luiz F., et al.
Publicado: (2011)

Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
por: Paccez, Juliano D., et al.
Publicado: (2019)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

The synergistic regulatory effect of Runx2 and MEF transcription factors on osteoblast differentiation markers
por: Lee, Jae-Mok, et al.
Publicado: (2010)

DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells
por: Unger, Florian T, et al.
Publicado: (2009)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
por: Gorski, Justin W., et al.
Publicado: (2021)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

A network model for angiogenesis in ovarian cancer
por: Glass, Kimberly, et al.
Publicado: (2015)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

GADD45α and γ interaction with CDK11p58 regulates SPDEF protein stability and SPDEF-mediated effects on cancer cell migration
por: Tamura, Rodrigo E., et al.
Publicado: (2016)

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
por: Zhang, Jinli, et al.
Publicado: (2017)

Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis
por: Wei, Shuqing, et al.
Publicado: (2017)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
por: Bamias, Aristotle, et al.
Publicado: (2006)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6bbd3peoavvhbslolloaugir38